Necessary for IL-12-Mediated Regression of the The CXC Chemokines IP-10 and Mig Are
暂无分享,去创建一个
[1] P. Leonard,et al. Interleukin-12 , 2012, BioDrugs.
[2] P. Wen,et al. Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors , 1995, Cancer Immunology, Immunotherapy.
[3] C. Bucana,et al. Expression of theJE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells , 1994, Cancer Immunology, Immunotherapy.
[4] J. Farber. Mig and IP‐10: CXC chemokines that target lymphocytes , 1997, Journal of leukocyte biology.
[5] J. Teruya-Feldstein,et al. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. , 1997, Blood.
[6] L. Koniaris,et al. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[7] S. Burdach,et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity , 1996, Nature Medicine.
[8] R. Whyte,et al. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases , 1996, The Journal of experimental medicine.
[9] Simon A. Jones,et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes , 1996, The Journal of experimental medicine.
[10] D. Goeddel,et al. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. , 1996, Human gene therapy.
[11] A. Angiolillo,et al. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. , 1996, Blood.
[12] J. Finke,et al. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. , 1996, Journal of immunology.
[13] J. Wigginton,et al. Antitumor activity of interleukin 12 in preclinical models , 1996, Cancer Chemotherapy and Pharmacology.
[14] Armen B. Shanafelt,et al. The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis (*) , 1995, The Journal of Biological Chemistry.
[15] L. Koniaris,et al. Human Mig chemokine: biochemical and functional characterization , 1995, The Journal of experimental medicine.
[16] P. Leder,et al. Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[17] M. Bar‐eli,et al. Suppression of tumor growth and metastasis of murine renal adenocarcinoma by syngeneic fibroblasts genetically engineered to secrete the JE/MCP-1 cytokine. , 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[18] D. Taub,et al. Human Interferon-inducible Protein 10 Is a Potent Inhibitor of Angiogenesis in Vivo , 1995 .
[19] P. Leder,et al. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation , 1995, The Journal of experimental medicine.
[20] Hendrzak Ja,et al. Interleukin-12. Biologic activity, therapeutic utility, and role in disease. , 1995 .
[21] R. Strieter,et al. Role of C‐X‐C chemokines as regulators of angiogenesis in lung cancer , 1995, Journal of leukocyte biology.
[22] B. Sykes,et al. Structure‐activity relationships of chemokines , 1995, Journal of leukocyte biology.
[23] R. D'Amato,et al. Inhibition of angiogenesis in vivo by interleukin 12. , 1995, Journal of the National Cancer Institute.
[24] J. Orange,et al. Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids , 1995, The Journal of experimental medicine.
[25] L. Luistro,et al. Role of Interferon‐γ in Mediating the Antitumor Efficacy of Interleukin‐12 , 1995 .
[26] M. Baggiolini,et al. Interleukin-8 and the chemokine family. , 1995, International journal of immunopharmacology.
[27] L. Luistro,et al. Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. , 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[28] G. Trinchieri. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. , 1995, Annual review of immunology.
[29] J. Tschopp,et al. A null mutation in the perforin gene impairs cytolytic T lymphocyte- and natural killer cell-mediated cytotoxicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[30] M. Dorf,et al. Inhibition of in vivo tumor growth by the beta chemokine, TCA3. , 1994, Journal of immunology.
[31] G. Trinchieri,et al. The role of interleukin 12 in the immune response, disease and therapy. , 1994, Immunology today.
[32] G. Trinchieri,et al. Interleukin 12, interferon gamma, and tumor necrosis factor alpha are the key cytokines of the generalized Shwartzman reaction , 1994, The Journal of experimental medicine.
[33] R. Schreiber,et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. , 1994, Journal of immunology.
[34] B. Dewald,et al. Structural requirements for interleukin-8 function identified by design of analogs and CXC chemokine hybrids. , 1994, The Journal of biological chemistry.
[35] M. Gately,et al. Antitumor activity of interleukin-12. , 1994, Clinical immunology and immunopathology.
[36] J. Finke,et al. Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with interferon-alpha and interleukin-2. , 1994, The American journal of pathology.
[37] C. Bucana,et al. Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. , 1994, Cancer immunology, immunotherapy : CII.
[38] L. Luistro,et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.
[39] A. Cesano,et al. Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12. , 1993, Journal of immunology.
[40] L. Azzoni,et al. Modulation of perforin and granzyme messenger RNA expression in human natural killer cells. , 1993, Journal of immunology.
[41] P. Leder,et al. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo , 1993, The Journal of experimental medicine.
[42] G. Trinchieri,et al. Interleukin-12 and its role in the generation of TH1 cells. , 1993, Immunology today.
[43] D. Taub,et al. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells , 1993, The Journal of experimental medicine.
[44] G. Trinchieri,et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells , 1993, The Journal of experimental medicine.
[45] E. Klein,et al. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. , 1993, Cancer research.
[46] E. Klein,et al. Cancer immunotherapy: are the results discouraging? Can they be improved? , 1992, Advances in cancer research.
[47] B. Rollins,et al. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells , 1991, Molecular and cellular biology.
[48] E. Podack,et al. A central role of perforin in cytolysis? , 1991, Annual review of immunology.
[49] J. Farber. A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[50] T. Sayers,et al. Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo. , 1990, Cancer research.
[51] G. Trinchieri,et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes , 1989, Journal of Experimental Medicine.
[52] Y. Ohmori,et al. IFN-gamma and IFN-beta independently stimulate the expression of lipopolysaccharide-inducible genes in murine peritoneal macrophages. , 1989, Journal of immunology.
[53] C. Tannenbaum,et al. Characterization of lipopolysaccharide-induced macrophage gene expression. , 1988, Journal of immunology.
[54] M. Brunda,et al. The anti‐tumor effect of recombinant interferon alpha or gamma is influenced by tumor location , 1987, International journal of cancer.
[55] S. Rosenberg,et al. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. , 1987, Journal of immunology.
[56] M. Brunda,et al. Differential antiproliferatve effects of combinations of recombinant interferons alpha and gamma on two murine tumor cell lines , 1986 .
[57] R. Tubbs,et al. Enzyme immunohistochemistry: technical aspects. , 1984, Seminars in diagnostic pathology.
[58] J. Sambrook,et al. Molecular Cloning: A Laboratory Manual , 2001 .
[59] W. Rutter,et al. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.
[60] M. Meltzer,et al. Tumoricidal responses in vitro of peritoneal macrophages from conventionally housed and germ-free nude mice. , 1976, Cellular immunology.
[61] U. K. Laemmli,et al. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.